The value of oncogene-focused patient-caregiver groups


Thanks to Dr. H. Jack West for the shout-out to our ros1cancer.com website and our page Drugs to Treat ROS1+ Cancer! Time to highlight that we are now in an era when pts w/rare cancers are increasingly likely to know more than docs, even very good ones, about their dzs. This @ros1cancer page on Drugs … Continue reading The value of oncogene-focused patient-caregiver groups

Should we combine TKIs and immunotherapy?


Some researchers think combining immunotherapy and certain targeted therapies called tyrosine kinase inhibitors (TKIs) may be too toxic for patients. This Phase 1/2 study supports that idea. It combined nivolumab and full-dose crizotinib in ALK+ non-small cell lung cancer, and was discontinued for safety reasons when 38% of the first 13 patients developed liver problems … Continue reading Should we combine TKIs and immunotherapy?

ROS1+ lung cancer patients in United Kingdom: we need your help!


To all ROS1+ non-small cell lung cancer (NSCLC) patients in the United Kingdom (UK): Please help advocate for coverage of crizotinib (Xalkori) for ROS1+ NSCLC through the UK’s national health system.  The Roy Castle Lung Cancer Foundation is putting together a submission on behalf of ROS1+ patients, and they are looking for patient experience quotes, preferably from the … Continue reading ROS1+ lung cancer patients in United Kingdom: we need your help!

IASLC Webinar 2018-02-06: Treatment Strategies for ROS1 Non-Small Cell Lung Cancer


This event is produced by the International Association for the Study of Lung Cancer (IASLC).  For more information and to register for the webinar, visit IASLC’s webinar registration page. If you are unable to participate in the webinar in real time, you can view the video on IASLC’s webinar page a few days after the webinar concludes.

Updated molecular testing guideline strongly recommends ROS1 testing for NSCLC


An 2018 update to the lung cancer molecular testing guideline says testing for ROS1 rearrangements is strongly recommended for all lung cancer patients regardless of clinical characteristics. The article “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors” was published online January 23, 2018, in the Journal of … Continue reading Updated molecular testing guideline strongly recommends ROS1 testing for NSCLC